This ITC suggests a trend toward greater efficacy and fewer adverse events for LTP with lanadelumab 150 mg versus LTP with C1-INH(IV) 1000 IU and 500 IU in pediatric patients with HAE. This evidence concerns the gene SERPING1 and hereditary angioedema.